Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.

Seminars in hematology - 1 Jul 1997

Rogers Z R

Abstract excerpt

Hydroxyurea (HU) is the first widely used treatment to have an impact on the severity of disease in adult patients with sickle cell anemia, but limited data are available for younger patients or those with variant genotypes. We reviewed 324 months of experience with HU in 16 patients from 5.3 to 18.4 years of age treated for 6 to 50 months. The major toxicity was reversible neutropenia. Linear growth continued...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Anemia, Sickle Cell
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Fetal Hemoglobin

Share to Genotype

Share to Globins

Share to Weight Gain

Source

Identifiers

PMID: 9317200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.PMID 9317200Read ↗

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension studySemantic proximity Read ↗

Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseSemantic proximity Read ↗

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.Semantic proximity Read ↗

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapySemantic proximity Read ↗

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Semantic proximity Read ↗

Hydroxyurea Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

Use of hydroxyurea in children with sickle cell disease: what comes next?Semantic proximity Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseSemantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaSemantic proximity Read ↗

Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan AfricaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.